Trial · NCT00304187
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
NCT00304187, Phase 2, Completed, New York State Psychiatric Institute; results first posted 2013-07-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa. Trials, record NCT00304187. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00304187
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
- NCT number
- NCT00304187
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 29 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Bulimia Nervosa, Eating Disorders
- Interventions
- Erythromycin, Placebo
- First posted
- 2006-03-17
- Last updated
- 2018-08-20
- Results first posted
- 2013-07-30
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Binge Frequency | Measured at Week 7 | Binge frequency was assessed by patient diary. All patients were asked to keep a diary of the number of daily binge eating and vomiting episodes which was collected at each weekly visit. |
| Primary | Percent of Meal Remaining/Minute | Measured at Week 7 | percent of meal remaining/minute |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Binge Frequency | Measured at Week 7 | Participants for analysis included 13 patients in the erythromycin and 13 patients in the placebo group who completed at least 5 weeks of drug treatment. | Binge Episodes/Week | MEAN |
| PRIMARY | Percent of Meal Remaining/Minute | Measured at Week 7 | percent of meal remaining/minute | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Binge Frequency | Erythromycin | 10.4 | Standard Deviation 8.7 | Binge Episodes/Week | |
| Binge Frequency | Placebo | 11.3 | Standard Deviation 10.9 | Binge Episodes/Week | |
| Percent of Meal Remaining/Minute | Erythromycin | -.339 | Standard Error .14 | percent of meal remaining/minute | |
| Percent of Meal Remaining/Minute | Placebo | -.177 | Standard Error .122 | percent of meal remaining/minute |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Erythromycin | 15 | |
| Overall Study | STARTED | Placebo | 14 | |
| Overall Study | COMPLETED | Erythromycin | 13 | |
| Overall Study | COMPLETED | Placebo | 13 | |
| Overall Study | NOT COMPLETED | Erythromycin | 2 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Erythromycin | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Erythromycin | 0 | 15 |
| Total, other adverse events | Placebo | 0 | 14 |
| Total, serious adverse events | Erythromycin | 0 | 15 |
| Total, serious adverse events | Placebo | 0 | 14 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH042206 | Psychobiology of Eating Behavior in Eating Disorders | WALSH, B. TIMOTHY | COLUMBIA UNIVERSITY HEALTH SCIENCES | NATIONAL INSTITUTE OF MENTAL HEALTH | 1987 to 2008 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Erythromycin vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00304187
GET https://conductscience.org/api/trials/v1/NCT00304187/registered